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The amyloid cascade hypothesis remains a robust model of AD neurodegeneration. However, amyloid deposits contain proteins
besides Aβ, such as apolipoprotein E (apoE). Inheritance of the apoE4 allele is the strongest genetic risk factor for late-onset
AD. However, there is no consensus on how diﬀerent apoE isotypes contribute to AD pathogenesis. It has been hypothesized
that apoE and apoE4 in particular is an amyloid catalyst or “pathological chaperone”. Alternatively it has been posited that apoE
regulates Aβ clearance, with apoE4 been worse at this function compared to apoE3. These views seem fundamentally opposed.
The former would indicate that removing apoE will reduce AD pathology, while the latter suggests increasing brain ApoE levels
may be beneficial. Here we consider the scientific basis of these diﬀerent models of apoE function and suggest that these seemingly
opposing views can be reconciled. The optimal therapeutic target may be to inhibit the interaction of apoE with Aβ rather than
altering apoE levels. Such an approach will not have detrimental eﬀects on the many beneficial roles apoE plays in neurobiology.
Furthermore, other Aβ binding proteins, including ACT and apo J can inhibit or promote Aβ oligomerization/polymerization
depending on conditions and might be manipulated to eﬀect AD treatment.

1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder
that is clinically characterized by progressive mental decline
and histopathologically defined by highly abundant amyloid
deposits and neurofibrillary tangles in the brain parenchyma. The identification of mutations within the amyloid precursor protein (APP) and presenilin (PS) genes that cause
autosomal dominantly inherited AD and that result in
increased production of amyloid-prone forms of Aβ established beyond doubt that the processing of APP and the
production of Aβ peptides are intimately involved in the
disease process and led to the proposal and the reinforcement
of the Alzheimer Amyloid Cascade Hypothesis [1, 2].
The role of amyloid in neuronal dysfunction has recently
been extended by the discovery of small, soluble, oligomers
of the Aβ peptide, some forms of which have been

termed ADDLs (Aβ-derived diﬀusible ligands), protofibrils,
or Aβ∗ 56 [3–6]. These Aβ oligomers are not only potential
intermediates in the formation of amyloid filaments, but
they also have been shown to be neurotoxic themselves and
to inhibit long-term potentiation (LTP), a cellular model of
memory, in hippocampal slices [4, 7, 8]. Thus, the Amyloid
Cascade Hypothesis now includes the essential role of Aβ
oligomers in the neurodegeneration process.
Despite its strength, the Amyloid Cascade Hypothesis is
incomplete without including the essential role of amyloidassociated inflammatory proteins. For example, biochemical
and histological studies first showed that, in addition to
Aβ, amyloid deposits also contained the inflammation/acute
phase protein α1-antichymotrypsin (ACT) [9] and, later,
apolipoprotein E (apoE) [10, 11], which were both hypothesized to serve as catalysts or “pathological chaperones” of
amyloid formation [9, 11, 12]. These and other results also
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indicated that Alzheimer’s disease and its manifestation in
middle-aged Down syndrome may include an inflammatory
process, for both ACT and apoE are inflammatory and/or
acute phase proteins in other contexts, and both are overexpressed in aﬀected regions of the AD brain (for reviews
see [13–15]). Indeed, Alzheimer himself first identified the
inflammatory component of Alzheimer’s disease when he
described reactive astrocytes and microglia in aﬀected brain
regions of his first patient [16]. However, until inflammatory
proteins such as ACT, IL-1, HLA, and apoE were found to be
overexpressed in AD and DS brains, the term “inflammation”
was explicitly excluded from the clinical and pathological
description of AD because of the lack of edema and
lymphocyte infiltration [9–11, 17, 18].
The significance of these biochemical results instigated
and was reinforced by parallel genetic discoveries implicating
a role for inflammation in AD. In particular, inheritance of
the apoE ε4 allele was found to be the strongest known risk
factor for AD besides age, with one copy increasing AD risk
3–5-fold and two copies over 10-fold [19–21]. Furthermore,
apoE ε4 promotes cognitive decline in middle-aged Down
syndrome individuals [22].
Because of apoE’s essential genetic, and therefore presumably biochemical, contribution to AD pathology and
cognitive decline, it is critical that its role in the AD pathogenic pathway/amyloid cascade be elucidated in order for
therapeutics based on apoE to be designed. While recent
excellent and encyclopedic literature reviews describe the
many potential roles that apoE plays in AD [23–26], this
focused review will concentrate on the interaction between
Aβ and apoE and other inflammatory proteins, on the eﬀects
of such interactions, and on their implications for designing
apoE-based AD therapies. The central question we try to
answer is whether increasing or decreasing apoE level and/or
function will serve best to reduce AD/DS pathology and cognitive decline. Lack of a clear answer may lead to the development of drugs that, rather than serving as an AD therapy,
instead potentially exacerbate the disease.

2. Background: ApoE as Amyloid Catalyst
To determine whether inflammation contributes to Alzheimer’s disease rather than being merely a correlative pathological feature in the AD brain, we and others tested the
hypothesis that ACT and/or apoE serve as amyloid catalysts
or pathological chaperones. Numerous in vitro and in vivo
studies showed that mature amyloid deposition and the associated cognitive decline is strongly stimulated by apoE and
ACT in a dose-dependent and isoform-specific manner, with
apoE4 being the strongest promoter of Aβ polymerization
and apoE2 being an inhibitor, paralleling the eﬀect of these
two isoforms in humans [27–38]. Indeed, without one or
the other of these amyloid catalysts expressed in the brain,
amyloid deposition is profoundly delayed in APP transgenic
mice and does not become filamentous. Such APP+/apoE
KO animals also exhibit normal cognition despite levels of Aβ
expression equal to the apoE-expressing APP animals. Elegant work by Manelli and colleagues also showed that native
lipidated apoE4 from transgene replacement astrocytes
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increases Aβ neurotoxicity compared to apoE3 or E2, indicating that apoE4 provides a negative gain of function [39].
Finally, Jones and colleagues recently showed that apoE4
also promotes the conversion and enhanced synaptic localization of Aβ as oligomers, the most neurotoxic form of the
Alzheimer amyloid peptide [40, 41]. These recent studies
extended prior work showing that apoE copurifies with Aβ
during biochemical isolation of amyloid from human brains,
and that apoE preferentially interacts with Aβ peptides in a
β-sheet structure [42–45].
Together these results show that inflammatory proteins,
particularly apoE, are integral parts of the amyloid cascade,
and that without them the cascade would be arrested at the
level of the harmless Aβ monomer, and no AD would ensue.

3. Background: ApoE in Aβ/Amyloid Clearance
The view of apoE as an integral and pathological part of the
amyloid cascade has been shaken by experiments that suggest
that apoE, far from being an amyloid catalyst, serves to clear
Aβ from the brain. Under this view, ApoE is protective,
with human apoE4 being less protective than apoE3 or E2
(for the most recent discussion, see [46] and commentary at
http://www.alzforum.com/).
The first experiments that suggested apoE’s role as a neuroprotector examined the pathology and cognition of APP
transgenic mice carrying a second transgene expressing one
or another human apoE isoform. Contrary to expectations,
amyloid deposition in these mice was inhibited by the human
apoE transgene, as though human apoE was protective [47].
Ultimately, the mice did develop amyloid, with the apoE4expressing strain accumulating earlier and more extensive
pathology [33, 34, 48, 49]. It was proposed that human apoE
might serve to inhibit Aβ clearance from the brain compared
to mouse apoE, with apoE4 inhibiting clearance the most.
Other experiments showed that indeed, clearance of Aβ
species was inhibited by complexing with apoE, especially
apoE4 [46, 50].
The possibility that interaction with apoE modulated
an Aβ clearance mechanism appeared to be supported by
the finding that introduction of anti-Aβ antibodies or other
Aβ-binding proteins such as gelsolin, led to a reduced
amyloid load in the brain and rapidly improved cognition,
with little evidence of Aβ-binding agents invading the brain
parenchyma [41–54]. We also introduced apoE itself into the
circulation via parabiosis and found that it induced amyloid
clearance without entering the brain in AD model mice
[38]. Thus the “Peripheral Sink Hypothesis” became a viable
alternative or addition to the Amyloid Cascade Hypothesis,
with apoE potentially playing an additional role as an Aβbinding peripheral protein.
Most recently, an approach to therapy has been investigated in AD mice that is based on activating the liver X receptor (LXR), which also exists on other cells including microglia [55–57]. Activation of LXR results in increased expression of many proteins including apoE and its lipidating
enzyme, ATP-binding Cassette Transporter A1 (ABCA1).
The results indicate that activating LXR with the ligand
GW3965 or the FDA-approved antiskin cancer drug
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bexarotene reduces soluble and insoluble Aβ and improves
cognition in APP Tg mice, while knocking out the ABCA1
gene in APP mice showed a tendency to reduced amyloid
load. Because apoE expression and lipidation is stimulated
by LXR activation, the results were interpreted as proof that
increased apoE levels help microglia clear Aβ and amyloid, as
indeed some earlier cell culture experiments had suggested.
However, it has also been shown that genetic overexpression
of ABCA1 reduces amyloid deposition in mice where the
apoE levels are unchanged [58]. Hence, because LXR stimulation influences the levels of many proteins, it is problematic
to definitively link its in vivo action to the altered level of
one particular protein. Furthermore, the increased levels of
ABCA1 induced by Bexarotene enhance apoE lipidation, a
change that is known to alter apoE/Aβ interactions. Hence, it
is important to consider the lipidation state of apoE, which
aﬀects its function, in addition to the absolute levels of
apoE.

4. Synthesis
When trying to distinguish and weigh the value of two hypotheses, it is instructive to consider their testable predictions.
If apoE is an amyloid catalyst, then reducing apoE levels
or function in the brain should result in reduced amyloid
deposition and reduced cognitive decline. If on the other
hand, apoE is involved in Aβ clearance with human apoE4
being a greater inhibitor of clearance (or poorer clearer), then
reducing apoE levels or apoE binding to Aβ should increase
amyloid deposition and cognitive decline.
All experiments carried out so far in vitro or in transgenic
mice indicate that the ability of Aβ to form neurotoxic filaments or oligomers and cause cognitive decline are increased in
the presence of apoE, particularly mouse apoE and human
apoE4, with apoE2 being protective. In contrast, in the
complete absence of apoE, the mutant APP gene and its
product Aβ are harmless, generating neither amyloid deposits, synaptic disfunction, or cognitive decline, with one copy
of apoE having an intermediate eﬀect, as discussed above.
The in vitro experiments in particular indicate that apoE
likely acts catalytically to promote Aβ polymerization, as the
molar ratio of Aβ to apoE of about 200/1 was appropriate for
the formation of neurotoxic products [27–30]. Most recently,
earlier work showing that mice expressing only one apoE
gene accumulated less amyloid than those with two apoE
genes (32) was repeated in two diﬀerent laboratories using
human apoE knock-in mice, and the same result was found,
that is, lower doses of apoE3 or apoE4 led to reduced amyloid
deposition [59, 60].
The simplest interpretation of the in vitro, cell culture,
and transgenic mouse data is that apoE is necessary for Aβ to
polymerize into neurotoxic oliogomers/filaments, probably
by binding to Aβ and thus altering its structure more toward
the β-sheet and more easily allowing successive Aβ peptides
to add on to the growing chain. The recent finding that
apoE promotes Aβ oligomer formation in vivo reinforces
this interpretation [40, 41]. Whether apoE is only needed to
initiate the polymerization or also to prepare each peptide
for addition to the growing filament is not yet known.
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Even though the key predictions of the polymerization
hypothesis, that is apoE serving as an Aβ filament catalyst,
have been borne out, the compelling experiments demonstrating that human apoE inhibits filament formation in a
mouse background require explanation. Furthermore, data
from LaDu and colleagues and by others have shown that
lipidated apoE, presumably the prevalent form in vivo, binds
Aβ with an aﬃnity of E2 > E3 > E4 [61–64]. Finally, the
elegant and thorough experiments of Castellano and colleagues show very convincingly that expression of a human
apoE4 transgene (in the absence of mouse apoE) leads to
a longer half-life, (i.e., slower clearance) of Aβ in the brain
interstitial fluid compared to E2 or E3 [46].
The apoE-Aβ binding studies might be interpreted as
support for apoE functioning in Aβ clearance because apoE2,
for example, would bind Aβ tightly and could thereby
promote its removal from the interstitial fluid via LRP
receptors [50, 61–64]. However, an important feature of any
catalyst is that it must bind its substrate only tightly enough
to convert it to the transition state structure and then release
it as the reaction is completed [65, 66]. If a mutation leads
to an overly tight substrate binding, then no further reaction
can occur. Thus apoE2 could indeed bind Aβ most tightly,
and thereby not only prevent apoE4 from binding and promoting Aβ oligo/polymerization, but also prevent the spontaneous polymerization of the peptide.
The ability of diﬀerent apoE isoforms to bind Aβ with
diﬀerent strengths can also explain why human apoE isoforms slow amyloid deposition in the presence of the endogenous mouse apoE, for they may bind Aβ more tightly
or diﬀerently than mouse apoE and slow the catalytic conversion of Aβ into oligomers/polymers in the mouse background.
The data showing that human apoE inhibits Aβ clearance
can also be interpreted as reflecting apoE’s role in catalyzing
Aβ oligo/polymerization. Pathologic macromolecular structures are often resistant to various clearance mechanisms
designed for monomeric species, whether by intracellular
proteasome degradation or cross-membrane/BBB transfer,
thus allowing their accumulation. Only when oligo/polymeric structures are anticipated and physiological clearance
mechanisms are in place to handle them, as for antibodyantigen complexes, will clearance be facilitated by conversion
to larger structures. Because apoE clearly has the ability to
catalyze the conversion of Aβ into oligomeric and polymeric
structures, it is reasonable to assume that those structures
will be more diﬃcult to clear, and that such diﬃculty will
be detected as clearance inhibition in the brain, for instance,
by apoE4, in pulse chase type experiments, while the higher
apoE levels in blood may aid the clearance of Aβ from the
circulations (Figure 1).
Finally, the ability of GW3965 and Bexarotene to reduce
soluble and insoluble Aβ in the brain of Tg APP mice and
improve cognition is most easily understood as resulting
from a general activation of the phagocytic activity of
microglia. Previous work showed that activation of microglia
by acute intracerebral treatment of APP mice with LPS or
with Granulocyte-macrophage stimulating factor can similarly reduce amyloid load and improve cognition [67–69] but

4

International Journal of Alzheimer’s Disease

Brain
ApoE + Aβ
E4 > E3 > E2

Oligomers/fibrils

(Poor clearance)

Blood
5−10xApoE + 0.03−1xAβ
Complexes
(Good clearance)

Figure 1: ApoE promotes Aβ Fibril formation in brain and Aβ
clearance from the blood. Data from both in vitro and in vivo
experiments indicate that apoE, especially apoE4 promotes the
polymerization of Aβ into oligomers and polymers that accumulate
in the brain and are diﬃcult to clear. In contrast, the concentration
of apoE is higher in the blood, while those of Aβ species are
equivalent to or lower than in the brain, promoting the formation
and clearance of equimolar apoE-Aβ complexes.

that long-term peripheral treatment with LPS exacerbated
amyloid deposition in an apoE-dependent manner [70].
Stimulation of microglial activity via induction of Toll-like
receptor 9 (TLR9) has also been shown to greatly reduce
amyloid load and improve cognition [71]. Clearly the interaction of neuroinflammation, microglia, and amyloid load is
complex, and the fact that bexarotene “cures” AD in mice is
more likely to be despite, rather than because it stimulates
expression of apoE.

5. Aβ Binding Proteins and AD Therapy
A good test of any hypothesis about the pathogenesis of a
disease is whether it successfully predicts how the pathogenesis can be inhibited or reversed. For example, small
fragments of Aβ corresponding to the amino acid sequences
to which ACT (Aβ1-12) and apoE (Aβ12-28) bind can serve
as decoy peptides that prevent the binding of apoE to Aβ
and its catalysis of Aβ into neurotoxic species [30]. This
early in vitro work has recently been repeated and confirmed
in other laboratories [72, 73]. The decoy principal was
extended in vivo by preparing a version of Aβ12-28 that has
a better plasma 1/2 life and is nonfibrillogenic/nontoxic. It
was shown that this peptide could be peripherally introduced
into a transgenic APP mouse, where it eﬀectively entered the
brain and prevented/reversed oligomer formation, amyloid
deposition, and cognitive decline [74–76]. Similarly, amyloid
plaques in APP mice contain mouse ACT and injecting
Aβ1-11 into one side of the APP mouse brain to block
ACT’s binding site with endogenous Aβ rapidly reduced
amyloid load compared to the other, vehicle-injected side
of the brain. Furthermore the inflammatory cytokine IL-1
that is overexpressed in AD brain [18] induces astrocyte
expression of ACT [77], and blocking IL-1 expression in APP
transgenic mice by Ibuprofen treatment, thereby reducing
mouse ACT expression, lowers amyloid formation and
restores cognition [78]. Evidently, blocking ACT or apoE

expression or function, both in vitro or in vivo, successfully
prevents Aβ pathology and neurotoxicity.
Apolipoprotein J also binds Aβ and can be shown to
aid its passage across the blood brain barrier [79–83]. Interestingly, knocking out either apoJ or apoE reduces amyloid
deposition in APP transgenic animals, yet knocking out
both leads to robust amyloid deposition at an even earlier
age than arises in nonmanipulated APP animals [84]. This
result may reflect the ability of mouse ACT to promote
amyloid formation, but that in the presence of the stronger
binding apoE and apoJ proteins mouse ACT is prevented
from exhibiting its catalytic activity.

6. Potential Efficacy and Dangers of
Aβ-Binding Antibodies as AD Therapy
The role of apoE and ACT in the Alzheimer pathogenic pathway has potentially general implications. One of the most
studied classes of Aβ binding proteins are specific anti-Aβ
antibodies, which form the basis of both passive and active
immunization therapies for Alzheimer’s disease (for review
see [85]). The finding that apoE and ACT can catalyze Aβ
oligo/polymerization begs the question of whether Aβ antibodies might also promote or inhibit Aβ polymerization.
Indeed we found that two Aβ antibodies, 6E10 which is
directed to the same the N-terminal sequence bound by
ACT, and 13 M, which binds to the C-terminus, function
very diﬀerently in the in vitro Aβ polymerization assay. 6E10
inhibits ACT-catalyzed polymerization of Aβ while 13 M
inhibits ACT catalysis much less and even promotes some
polymerization itself. Interestingly, the N-terminus of Aβ is
also the target of many attempts at AD immunotherapy with
the aim of inducing microglial phagocytosis of neurotoxic Aβ
species. Yet removing the microglial-binding Fc portion of
3D6 antibodies to Aβ1-5 to generate Fab’2 fragments does
not reduce the antibody’s ability to remove diﬀuse amyloid
in APP mice [86]. Evidently, only its Aβ-binding feature is
required to allow the antibody to remove amyloid. A possible
explanation for this result is that the antibody functions by
blocking Aβ interaction with mouse ACT. The consequent
suppression of ACT-catalyzed oligo/polymerization could
thus tilt the dynamic process of plaque development toward
depolymerization.
These results illustrate the fact that Aβ-binding proteins
can have multiple eﬀects on polymerization and that their
full range of activities must be considered when using them
as potential targets or tools for therapeutic intervention.

7. Potential Toxic Mechanism of
ApoE-Induced Aβ Oligomers
Although Aβ oligomers have been shown to be highly
neurotoxic in vitro and in vivo, and their formation is promoted by apoE4, the mechanism of their toxicity is still
being elucidated. The data reviewed above coupled to other
recent findings suggest a novel mechanism for Aβ toxicity
that encompasses the essential role of apoE. Specifically, Aβ
oligomers bind to and inhibit certain microtubule motors
that are essential for the function and stability of the mitotic
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Figure 2: Conceptual energy diagram of ApoE-catalyzed Aβ oligo/polymerization. Although Aβ can polymerize spontaneously, the reaction
is greatly promoted by apoE in vitro and in vivo. This catalysis can be understood in terms of the energy diagram shown. The first energy
change, a reduction, occurs as apoE binds to amino acids 12–28 of Aβ, with diﬀerent apoE isoforms binding with diﬀerent aﬃnities. Then
apoE apparently alters the structure of its bound Aβ to a higher-energy β-sheet conformation (the transition state), which allows additional
Aβ molecules to add and form a larger oligomer or fibril. These products have lower energy than either the transition state or the initial
reactants (apoE and Aβ), thus driving the reaction to completion. Because the energy of the apoE-Aβ transition state is lower than either
the transition state of monomeric Aβ in a β-sheet conformation, the oligo/polymerization reaction is eﬀectively catalyzed by apoE. ApoE4
evidently forms the lowest energy transition state and thus strongly catalyzes the reaction, apoE3 catalyzes the reaction less well, and apoE2
likely forms such a high energy transition state that it eﬀectively inhibits the spontaneous Aβ polymerization reaction. Antichymotrypsin
(ACT), which binds to Aβ amino acids 1–12, also catalyzes Aβ polymerization, while Aβ antibodies can either promote Aβ fibrillization
themselves or interfere with ACT or apoE-catalyzed polymerization. Molecules, including antibodies, that prevent apoE or ACT binding to
Aβ are being developed as AD therapies that leave the normal physiological functions of Aβ and apoE or ACT intact, while blocking their
pathological interaction.

spindle—Eg5/kinesin5, Kif4A, and MCAK [87]. Similar
motors, including kinesin 5, are also present in mature neurons [88, 89]. We have found recently that inhibition of MT
motor function by Aβ or by the specific kinesin 5 inhibitor
Monastrol prevents the eﬃcient transport of receptors such
as the LDLR, the NMDA neurotransmitter receptor, and
the p75 neurotrophin receptor to the cell surface, resulting
in reduced function ([90]; in preparation). Similarly, apoE,
particularly apoE4, has been shown to reduce the cell surface
levels and function of NMDA, AMPA, and apoEr2 receptors in neurons [91]. This latter finding can now be understood as potentially reflecting the ability of apoE4 to promote
the conversion of endogenous neuronal Aβ into oligomers,
which then inhibit MT-based transport of key cellular components such as receptors to their functional location.

8. Conclusion
In sum, it appears that the preponderance of the data can
be most consistently interpreted as showing that the brain
inflammatory protein apoE plays a catalytic role in the
AD/DS amyloid cascade and consequent cognitive decline,
with binding and clearance diﬀerences between the apoE
isoforms reflecting their diﬀering abilities to bind to Aβ
and catalyze its conversion into neurotoxic macromolecular

species (Figure 2). This conclusion, and the in vivo demonstration that blocking apoE-Aβ interaction prevents AD in
a mouse model, suggests that this decoy approach should be
translatable into human patients and serve as an eﬀective new
approach to AD therapy.
Other Aβ-binding proteins may be similarly manipulated
by a decoy approach to reduce oligomerization and polymerization of Aβ into neurotoxic species. However, the finding that diﬀerent antibodies to Aβ can both inhibit ACTcatalyzed Aβ polymerization and promote polymerization of
Aβ itself, argues that immunotherapy must be approached
with care to avoid the use or induction of antibodies that
can catalyze further oligo/polymerization of Aβ, instead of
inducing its phagocytosis and removal. Furthermore, human
and mouse intracerebral environments may diﬀer in important ways with respect to the pattern and activities of Aβbinding proteins and may also respond diﬀerently to intervention or inflammation. Such diﬀerences may explain why
so many treatments that were successful in reducing amyloid-dependent cognitive decline in transgenic mice have
failed to translate into human AD patients.
Finally, the ability of Aβ oligomers to inhibit key microtubule motors and prevent the transport of neurotrophin,
neurotransmitter, and other receptors to the cell surface may
underlie their neuronal toxicity. It is apparently the ApoE-,
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especially E4-dependent formation of such Aβ oligomers,
that constitutes the key catalytic step in the AD pathogenic
pathway.
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